20 Oct

Johnson and Johnson’s 3Q15: Growth of Consumer Healthcare

WRITTEN BY Mike Benson

The Consumer Healthcare segment

Johnson & Johnson’s (JNJ) consumer healthcare segment grew by 3.1% at constant exchange rates, reporting a revenue of ~$3,314 million for 3Q15 over 3Q14. The foreign exchange impacted this segment negatively by 10.8% during the quarter, making an overall fall of 7.7% in revenues for this segment.

Johnson and Johnson’s 3Q15: Growth of Consumer Healthcare

Baby care franchise

The baby care franchise sales rose by 2.0% at constant exchange rates due to the successful launch of new baby care products, partially offset by lower sales of cleansers and creams primarily due to competition in China. The baby care franchise contributed ~15.3% of the segment’s sales for 3Q15.

Oral care franchise

The oral care franchise sales improved 3.5% at constant exchange rates, following the launch of new products under the Listerine brand and successful marketing campaigns. The oral care franchise contributed ~11.4% of the segment’s sales for 3Q15.

Over-the-counter franchise

Over-the-counter (OTC) franchise sales improved 6.3% at constant exchange rates, following the growth of analgesics and Zyrtec—an allergy medication—in the United States. Results outside the United States were negatively impacted by the timing of seasonal inventory build for the upper respiratory products. The OTC franchise contributed ~29.0% of the segment’s sales for 3Q15.

Skin care franchise

Skin care franchise sales improved by 2.5% at constant exchange rates, following strong sales of Aveeno and Neutrogena products, partially offset by soft sales in China. Skin care contributed ~26.0% of total segment sales for 3Q15.

Women’s health franchise

Women’s health franchise sales improved ~13.3% at constant exchange rates, following the launch of new products and successful marketing campaigns outside US markets. The women’s health franchise contributed ~9.3% of total segment sales for 3Q15.

Wound care and other franchise

Wound Care franchise sales fell by ~11.9% at constant exchange rates, due to the divestiture of the Benecol brand outside US markets, completed in November 2014. This franchise contributed ~8.8% of total segment sales for 3Q15.

For the Consumer Products segment, other major companies include Unilever NV (UN), Nestle S.A. (NSRGY), Kimberly-Clark Corporation (KMB), and Procter & Gamble (PG). Investors can consider ETFs like the VanEck Vectors Pharmaceutical ETF (PPH), investing 7.4% of its portfolio in Johnson & Johnson.

Latest articles

CrowdStrike (CRWD) fell 9.5% today to close at $54.52. Analyst Walter Pritchard initiated coverage on CRWD with a “sell” rating and a target price of $43.

Micron (MU) stock was up 4.21% on Friday and closed at $45.10. MU was trading 12.2% below its 52-week high of $51.39 for a market cap of $49.9 billion.

Top utility stocks trended lower and lost 1.3% last week. Broader markets were positive but cautious on trade talk optimism, gaining 0.7% last week.

Analyst Ming-Chi Kuo expects Apple to launch the iPhone SE2 in Q1 2020. Priced at $399, it could help Apple gain traction in India and Southeast Asia.

Disney-owned Hulu plans to introduce video downloads, which Netflix has offered for three years. Disney hopes to narrow Netflix’s competitive advantage.

Ireland’s privacy watchdog has concluded its investigation into Facebook over its compliance with the European Union’s data protection law.